The acquisition increases Altasciences' small molecule expertise, as well as adds pharmacology, ophthalmology, and carcinogenicity efficacy study capabilities to its current preclinical offering, the company reported in a statement.

Altasciences is a CRO that supports steps in early-stage drug development. Michael Recny, PhD, is the outgoing CEO of Calvert Laboratories.

Report finds CROs modernizing, accelerating clinical trials
Contract research organizations (CROs) are modernizing and speeding up clinical trials with 90% unifying their clinical operations, according to a new...

Science 37 launches CRO program for decentralized clinical trials
Science 37 has launched a partnership program called Science 37 Certified, which is designed to empower contract research organizations (CROs) with access,...

How is the pharma-AI partnership landscape changing?
Artificial intelligence (AI) is taking on a growing role in drug discovery and development, with some 250 firms in a market space that's worth over $9 billion....

Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider.